UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Earnings for UroGen Pharma Ltd. (URGN)
Earnings in 2023 (TTM): $-98,324,000
According to UroGen Pharma Ltd.'s latest financial reports the company's current earnings (TTM) are $-98,324,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of UroGen Pharma Ltd.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-98,324,000 | $-102,244,000 |
| 2022 | $-108,028,000 | $-109,163,000 |
| 2021 | $-109,371,000 | $-110,820,000 |
| 2020 | $-125,110,000 | $-128,484,000 |
| 2019 | $-105,146,000 | $-100,530,000 |
| 2018 | $-75,532,000 | $-75,657,000 |
| 2017 | $-19,981,000 | $-20,000,000 |
| 2016 | $-1,941,000 | $-1,941,000 |
| 2015 | $-12,689,000 | $-12,689,000 |
| 2014 | $-4,476,000 | $-4,557,000 |
| 2013 | $-3,306,000 | $-3,306,000 |